Six members of the UH community participated in the inaugural Innov8 Hub's Innovators to Founders Cohort. Photo via UH.edu

A new accelerator at the University of Houston recently wrapped its first program for a cohort of five early-stage startups.

Known as the Innov8 Hub's Innovators to Founders Cohort, the accelerator is a founder-driven program in partnership with the UH Technology Bridge, the Innovation Center, and the Texas Gulf Coast Small Business Development Center (SBDC). Innov8 is designed to aid six to eight aspiring entrepreneurs bring their concepts to market and assist them in applying for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants.

Founders recently showcased their work before potential partners and investors at the hub's first-ever Startup Pitch Day following the conclusion of the 12-week program.

“The goal of the programs is for the founders to launch new ventures and develop business plans they can use to raise money and attract C-suite level employees to join their team,” Tanu Chatterji, associate director of startup development at Tech Bridge and co-founder of Innov8 Hub, said in a statement. “These programs aren’t classroom-teacher driven so the founders have to commit to engage and spend the time necessary to reap the benefits.”

The Innovators to Founders Cohort runs for three months each semester. Cohort members will devote three hours each week to the program. Photo via UH.edu

The inaugural cohort included:

Shoujun Xu, UForce Biotechnology: Xu is a chemistry professor at UH and has developed a new technique of super-resolution force spectroscopy, or SURFS, and plans to launch his company, UForce Biotechnology, in the future. He aims to use the SURFS technique to advance drug screening. His pitch at the Startup Pitch Day was named the best of the night, and Xu went home with $7,500 in legal services and one year of coworking space free of charge.

Easy Anyama, ODX Health: Anyama is a fourth-year student in the UH College of Optometry. His company, ODX Health, aims to improve "data harmonization, interoperability and integration in eyecare to reduce inefficiencies and enhance health outcomes," according to UH.

Jeremy Tee and Easy Anyama, Ringit: Anyama joined fellow fourth-year student in the UH College of Optometry Jeremy Tee in a second pitch, Ringit. The startup aims to provide a low-cost medication management solution for the visually impaired. It is developing an adaptive labeling system that helps the visually impaired identify their medication and dosages independently via intuitive, "touch-based features," according to UH.

Jan Beetge, AltiSora: Beetge has developed "Botox for wood." The product is made from high- sustainability raw materials that are non-hazardous and non-toxic. Potential applications include waterproofing of electronic equipment or electrical cables or connections in cables, such as cables used in marine applications, according to the company's website.

Jason Shi, Smart Planter Project: Shi is developing a "high-tech planter, a device that autonomously takes care of your plants and keeps them healthy while you’re gone," according to UH. He aims to soon test the product with customers.

The Innovators to Founders Cohort runs for three months each semester. Cohort members will devote three hours each week to the program.

The Innov8 Hub also offers an SBIR/STTR Support Cohort and a WKI Program for Student Entrepreneurial Support Cohort.

Last year, UH also named eight graduate students to its first-ever UH-Chevron Energy Graduate Fellows cohort.
Ramanan Krishnamoorti, vice president of energy and innovation at the University of Houston, joins the Houston Innovators Podcast to talk about the university's dedication to helping the city become an innovative force. Photo via UH.edu

University leader calls for shift in culture to advance Houston innovation

HOUSTON INNOVATORS PODCAST EPISODE 187

Ramanan Krishnamoorti has had a varied career in academia, from an engineering professor to nanotech research. While he never made the transition from researcher to entrepreneur, he managed to snag a CEO title at the university about a decade ago: Chief energy officer.

Since then his role has expanded to include advancing UH's innovation of all kinds — from health tech to the arts — as vice president of energy and innovation at UH. In his role, he oversees the UH Technology Bridge, a lab and coworking space for tenants just a short drive away from UH's main campus, as well as future plans, like a new central campus hub for innovation that's in its early stages of development.

"What we really need at the university today is to bring innovation — which tech transfer is a piece of — and connect that to real-world challenges to deliver what the world needs, which is talented folks delivering new innovative, entrepreneurial, or intrapreneurial programs," Krishnamoorti says on this week's episode of the Houston Innovators Podcast.

For Krishnamoorti, so much of what is happening on campus is directly in line with what's happening city wide in Houston. There's a need to encourage more innovation and entrepreneurship, he says, and Houston already has what it takes to do it.

"As a city, we're known to solve problems," he says on the show. "We don't talk about things here, we get stuff done. That's been the calling card for the city."

A priority for Krishnamoorti is making sure that UH has a culture — for students, faculty, and the entire community — that embraces creativity.

"We've got some incredibly innovative staff and faculty, and one of the things we do very well in academia, in spite of everything we talking about, is that we know how to stifle that creativity, especially when it comes to staff and faculty," Krishnamoorti says. "How do we change that culture?"

"Culture is the dominate thing," he continues. "We've got to be systematic about it. If we don't deliver that cultural shift about how we unleash creativity and innovation amongst our student, staff, faculty, and alumni, we're going to fail."

Krishnamoorti shares more about his vision for UH's future as a hotspot for innovation, as well as the challenges the organization faces, on the podcast. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

TexPower's founders — Board Chairman Arumugam Manthiram, CTO Wangda Li, and CEO Evan Erickson, respectively — celebrated the opening of the company's new lab space. Photo courtesy of TexPower

Houston startup with revolutionary battery technology opens new labs

power move

A Houston startup founded off research out of a Texas university has cut the ribbon on its new lab space.

TexPower EV Technologies Inc. celebrated the opening of its 6,000-square-foot laboratory and three-ton-per-year pilot production line at a ribbon-cutting event last week. The Northwest Houston site is located at 6935 Brittmoore Rd.

The new space will help the company further commercialize its cobalt-free lithium-ion cathode, lithium nickel manganese aluminum oxide (NMA). The technology is game changing for the electrification of the United States, including the rapid adoption of electric vehicles.

Currently, the country is experiencing a supply chain crisis, says Evan Erickson, co-founder and CEO of the company, at the event. Most of the world's cobalt, a material traditionally used in lithium-ion cathodes, is sourced primarily from the Congo and refinement is mostly controlled by China, he explains.

For these reasons, Cathodes are the most expensive component of lithium-ion batteries. But TexPower has a unique technology to solve this supply chain issue, and now with its new labs, is one step closer to commercialization of its materials.

TexPower spun out of the University of Texas at Austin in 2019. The company was co-founded by Erickson with CTO Wangda Li and Board Chairman Arumugam Manthiram, a professor at UT whose lithium-ion battery research fuels the foundation of the company.

“We want to point out how lucky we are — as a company and as scientists," Erickson says at the ribbon cutting event. "It’s not common that you see something you work on in academia turn into something that can become commercially successful.”

Prior to the newly built labs, TexPower operated out of the University of Houston's Tech Bridge. The company intends to raise additional funding to support its expansion.

According to the company, the new three-ton-per-year pilot line is the first step toward building a manufacturing facility that's capable of producing up to 50 times more the amount of cathode with a goal to impact markets such as defense, power tools, and eVTOL.

CEO Evan Erickson celebrated the new lab space opening last week

Photo courtesy of TexPower

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

4 Houston health tech startups advancing medical innovation

meet the finalists

Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

InformAI Inc.

InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Skybound MedTech

Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.